SCHEMBL30051147

SCHEMBL30051147

NCCNc1ccc2nc[nH]c2c1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 1/20 0.51
ADRA2C P18825 1/20 0.51
ADRA1D P25100 1/20 0.51
ADRA1A P35348 1/20 0.51
ADRA1B P35368 1/20 0.51
QPCT Q16769 9/20 0.50
CDK1 P06493 2/20 0.50
PRKCI P41743 1/20 0.50
KDM4E B2RXH2 1/20 0.49
MAPT P10636 1/20 0.49
RAD52 P43351 1/20 0.49
NAMPT P43490 1/20 0.47
MMP12 P39900 1/20 0.46
EPHX1 P07099 1/20 0.46
POLB P06746 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
BCDIN3D Q7Z5W3 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28931425 1.00 ADRA2A (0.51) ADRA2AADRA2CADRA1DADRA1AADRA1B
SCHEMBL2484239 0.81 EPHX1 (0.60) ADRA2AADRA2CADRA1DADRA1AADRA1B
SCHEMBL12257241 0.80 ADRA2A (0.54) ADRA2AADRA2CADRA1DADRA1AADRA1B
SCHEMBL17315551 0.79 IP6K1 (0.64) SMN1; SMN2
SCHEMBL24819761 0.79 ADRA2A (0.47) ADRA2AADRA2CADRA1DADRA1AADRA1B
SCHEMBL6625320 0.78 ADRA2A (0.58) ADRA2AADRA2CADRA1DADRA1AADRA1B
SCHEMBL24819763 0.77 EPHX1 (0.46) ADRA2AADRA2CADRA1DADRA1AADRA1B
SCHEMBL2541647 0.76 ADRA2A (0.50) ADRA2AADRA2CADRA1DADRA1AADRA1B
SCHEMBL2536231 0.76 QPCT (0.67) ADRA2AADRA2CADRA1DADRA1AADRA1B
SCHEMBL5063947 0.74 ADRA2A (0.58) ADRA2AADRA2CADRA1DADRA1AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346562-A1 OCT4 HIGH-SELECTIVITY ACTIVATOR IREGENE THERAPEUTICS LTD (CN) 2025-11-13 US disclosed
CN-115572285-B OCT4 high-selectivity activator 武汉睿健医药科技有限公司 2024-10-29 CN disclosed
EP-4361131-A1 OCT4 HIGH-SELECTIVITY ACTIVATOR Iregene Therapeutics Ltd (CN) 2024-05-01 EP disclosed
CN-115572256-A OCT4 high selectivity activator 武汉睿健医药科技有限公司 2023-01-06 CN disclosed
CN-115572285-A OCT4 high selectivity activator 武汉睿健医药科技有限公司 2023-01-06 CN disclosed
WO-2022266794-A1 OCT4 HIGH-SELECTIVITY ACTIVATOR 武汉睿健医药科技有限公司 2022-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346562-A1 OCT4 HIGH-SELECTIVITY ACTIVATOR POU2F1, POU5F1, POU2F2 ADRA2A 149/4885ADRA2C 822/4885ADRA1D 535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.